You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

Philip Ashman Biography and Net Worth

COO of Alimera Sciences

Dr. Philip Ashman Ph.D. serves as Chief Operating Officer, Senior Vice President - Commercial Operations Europe of the Company. He has served as Chief Operating Officer and Senior Vice President Commercial Operations Europe since January 2019. Previously, Dr. Ashman served as the Senior Vice President, Managing Director Europe since January 2013. Prior to joining us, Dr. Ashman held a number of leadership roles at Bayer from 2006 to 2012, including being responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including ophthalmology. Prior to this, Dr. Ashman served as Vice President Global Marketing Oncology at Bayer and also as Vice President Regional Business Unit Head (Europe) Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa. Before 2006, Dr. Ashman held UK-based business leadership positions in AstraZeneca and Sanofi. Dr. Ashman holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.

What is Philip Ashman's net worth?: The estimated net worth of Philip Ashman is at least $66,663.76 as of April 8th, 2021. Dr. Ashman owns 19,379 shares of Alimera Sciences stock worth more than $66,664 as of April 19th. This net worth estimate does not reflect any other assets that Dr. Ashman may own. Additionally, Dr. Ashman receives a salary of $389,860.00 as COO at Alimera Sciences. Learn More about Philip Ashman's net worth.
How old is Philip Ashman?: Dr. Ashman is currently 59 years old. There are 4 older executives and no younger executives at Alimera Sciences. The oldest executive at Alimera Sciences is Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets, who is 60 years old. Learn More on Philip Ashman's age.
What is Philip Ashman's salary?: As the COO of Alimera Sciences, Inc., Dr. Ashman earns $389,860.00 per year. There are 2 executives that earn more than Dr. Ashman. The highest earning executive at Alimera Sciences is Mr. Richard S. Eiswirth Jr., CEO & Director, who commands a salary of $597,870.00 per year. Learn More on Philip Ashman's salary.
How do I contact Philip Ashman?: The corporate mailing address for Dr. Ashman and other Alimera Sciences executives is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. Alimera Sciences can also be reached via phone at (678) 990-5740 and via email at [email protected]. Learn More on Philip Ashman's contact information.
Has Philip Ashman been buying or selling shares of Alimera Sciences?: Philip Ashman has not been actively trading shares of Alimera Sciences during the last quarter. Most recently, Philip Ashman sold 45 shares of the business's stock in a transaction on Thursday, April 8th. The shares were sold at an average price of $9.62, for a transaction totalling $432.90. Following the completion of the sale, the chief operating officer now directly owns 19,379 shares of the company's stock, valued at $186,425.98. Learn More on Philip Ashman's trading history.
Who are Alimera Sciences' active insiders?: Alimera Sciences' insider roster includes Philip Ashman (COO), Richard Eiswirth, Jr. (CEO), John Jones (CFO), and James Largent (Director). Learn More on Alimera Sciences' active insiders.
Are insiders buying or selling shares of Alimera Sciences?: During the last year, Alimera Sciences insiders bought shares 2 times. They purchased a total of 1,980,901 shares worth more than $4,346,041.70. The most recent insider tranaction occured on September, 14th when Major Shareholder Caligan Partners Lp bought 579,000 shares worth more than $1,962,810.00. Insiders at Alimera Sciences own 31.4% of the company. Learn More about insider trades at Alimera Sciences.
Information on this page was last updated on 9/14/2023.

Philip Ashman Insider Trading History at Alimera Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/8/2021	Sell	45	$9.62	$432.90	19,379
1/19/2018	Sell	25,500	$1.20	$30,600.00	12,750
1/17/2018	Sell	25,500	$1.23	$31,365.00	38,250

Philip Ashman Buying and Selling Activity at Alimera Sciences

Alimera Sciences Company Overview

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Today's Range

Now: $3.44

$3.27

$3.66

50 Day Range

MA: $3.73

$3.25

$4.21

2 Week Range

Now: $3.44

$1.56

$4.38

Volume

56,731 shs

Average Volume

78,484 shs

Market Capitalization

$180.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

You’re invited: Biggest crypto event of 2024

From InvestorPlace | Ad

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

Philip Ashman Biography and Net Worth

What is Philip Ashman's net worth?

How old is Philip Ashman?

What is Philip Ashman's salary?

How do I contact Philip Ashman?

Has Philip Ashman been buying or selling shares of Alimera Sciences?

Who are Alimera Sciences' active insiders?

Are insiders buying or selling shares of Alimera Sciences?